Venlafaxine deprescribing and thyroid function
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-06 · 43 (6) · 570-573
DOI: 10.1002/phar.2803 ↗At a glance
Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-04-26. Written by Barbara J Zarowitz and 1 co-authors. Institution: Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA. Major MEDLINE topics: Deprescriptions, Hashimoto Disease. Cited 4 times so far (Crossref); 21 references.
Abstract (original language)
Study Objective This report highlights the effects of discontinuing venlafaxine on thyroid function in an older adult with previously well‐managed Hashimoto thyroiditis and sleep apnea.
Design
Concurrent intervention. Case study.
Setting
Community‐based psychiatry practice Patient ‐ 66 year old female Intervention Over 8 months, a 66‐year‐old patient slowly reduced the venlafaxine dose. She was treated simultaneously for sleep apnea.
Measurements
Clinical data including venlafaxine and levothyroxine dosing, thyroid hormone laboratory values, subjective complaints, and objective electrocardiographic (ECG) findings were aggregated and analyzed. Main Results As venlafaxine dose was decreased over time, the patient complained of bounding heart palpitations shown to be premature ventricular contractions, and wide and narrow complex ventricular tachycardia on ECG. Thyroid‐stimulating hormone decreased from a baseline value of 0.791 uIU/mL to a nadir of 0.18 uIU/mL during venlafaxine dosage reduction from 225 mg/day to 155 mg/day. Cardiac symptoms subsided following levothyroxine dosage reduction.
Conclusions
There was a direct relationship between antidepressant dosage reduction and levothyroxine dosage requirements. Cautious monitoring is recommended during venlafaxine deprescribing in patients with pre‐existing thyroid disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Peter Lamy Center on Drug Therapy and Aging, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
- Cairn Center, Las Vegas, Nevada, USA.
ORCID profiles: Barbara J Zarowitz
Cite
APA
Zarowitz, B. J., & Jain, S. (2023). Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(6), 570-573. https://doi.org/10.1002/phar.2803
Vancouver
Zarowitz BJ, Jain S. Venlafaxine deprescribing and thyroid function. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(6):570-573. doi:10.1002/phar.2803
BibTeX
@article{Zarowitz2023,
author = {Zarowitz, Barbara J and Jain, Shaily},
title = {Venlafaxine deprescribing and thyroid function},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {6},
pages = {570--573},
doi = {10.1002/phar.2803}
}
EUVIMED